Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash

Sarepta Therapeutics, Inc.

Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.
New 4.875% notes are part of same series as $602M issued Aug 2025; post-exchange total $893.4M outstanding.
Approximately $158.6M of existing 1.25% notes will remain outstanding with unchanged terms.
Placement agent intends to buy ~691,000 SRPT shares in private transactions from exchanging investors at a discount.
Exchange expected to close on or about December 18, 2025, subject to customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.